Roberta Lipson, President and CEO of Chindex said, "We are pleased to see our arrangements with Fosun progressing as planned and announced. We welcome their participation and expertise as one of our major shareholders. Their credibility and presence in China is an asset to us as we execute our plan to build the leading network of premium care hospitals and clinics across the country. We continue to work towards the consummation of our previously- announced joint venture with Fosun Pharma in medical device manufacture and distribution. Fosun Pharma already operates in this area, and the addition of our medical products division is a great fit which should drive scale and a deeper presence across China."

Chen Qiyu, Chairman of Fosun Pharma said, "We are happy to be increasing our investment in Chindex. Fosun Pharma and Chindex are combining our strengths in healthcare and look forward to growing together in the future. We believe the demand for premium healthcare services which is served by Chindex's United Family Healthcare will continue to accelerate as China's economy grows. We are also excited about our future joint venture with Chindex in medical devices which we believe will leverage the value of the Chindex brand name in China's healthcare industry."

SOURCE Chindex International, Inc.